Show simple item record

dc.contributor.authorEkins, Sean, et al.
dc.date.accessioned2020-05-05T02:06:45Z
dc.date.available2020-05-05T02:06:45Z
dc.date.issued2020-03-25
dc.identifier.urihttps://doi.org/10.1007/s11095-020-02799-8en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/1303
dc.description.abstractFor the last 50 years we have known of a broad-spectrum agent tilorone dihydrochloride (Tilorone). This is a small-molecule orally bioavailable drug that was originally discovered in the USA and is currently used clinically as an antiviral in Russia and the Ukraine. Over the years there have been numerous clinical and non-clinical reports of its broad spectrum of antiviral activity. More recently we have identified additional promising antiviral activities against Middle East Respiratory Syndrome, Chikungunya, Ebola and Marburg which highlights that this old drug may have other uses against new viruses. This may in turn inform the types of drugs that we need for virus outbreaks such as for the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Tilorone has been long neglected by the west in many respects but it deserves further reassessment in light of current and future needs for broad-spectrum antivirals.en_US
dc.languageEnglishen_US
dc.subjectCOVID-19en_US
dc.titleTilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyonden_US
eihealth.countryOthersen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typeResearch protocol informationen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalPharmaceutical Researchen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record